^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
Excerpt:
...- Patients who were resistant to EGFR targeted treatment need to receive T790M mutation test....
Trial ID:
Source:
Title:
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
Excerpt:
...T790M, 19 exon deletion and L858R) external pathological examination was accepted (including pathological or blood test results)...
Trial ID:
More C2 evidence
Source:
Title:
Study for efficacy and safety of Anlotinib combined with TKI in advanced NSCLC patients after TKI treatment failure
Excerpt:
...After the first-line treatment with first-generation TKI, patients with slow disease progression were tested again for negative T790M; 6. ...
Trial ID:
Source:
Title:
An exploratory clinical study, to evaluate the efficacy of three generations of TKI inhibitors combined with anlotinib by 18F-FDG PET/CT dynamic imaging as First-Line Treatment in patients with EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Excerpt:
...EGFR mutation was confirmed by pathology, regardless of T790M mutation; 8. ...
Trial ID:
Less C2 evidence
Source:
Title:
Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
Published date:
06/30/2023
Excerpt:
Our multicenter study retrospectively collected 268 osimertinib-resistant NSCLC patients with EGFR T790M mutation and explored the efficacy of anlotinib in patients and in vitro….PFS was significantly longer in the anlotinib-based group than in the bevacizumab-based group (HR:0.58, p = 0.010). The median OS was 12.81 (95% CI: 10.31–15.32) months in the anlotinib-based group and 10.46 (95% CI: 9.75–11.16) months in the bevacizumab-based group (Figure 4C).
DOI:
https://doi.org/10.1002/cam4.6232
Source:
Title:
OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR.
Published date:
05/16/2018
Excerpt:
In 18 pts with T790 mutation, mPFS of 10 pts in anlotinib and 8 pts in placebo group were 3.27 vs. 0.83 month (P< 0.0001, HR = 0.044)...The PFS of 7 pts in anlotinib and 3 pts in placebo arm with previous osim treatment were 4.00 vs. 0.40 month (P= 0.0076, HR = 0.108), and OS were 10.10 vs. 2.20 month (P= 0.03, HR = 0.071), respectively....Anlotinib revealed an optimistical trend in PFS than placebo in pts with T790 mutation or resistance to osim.
DOI:
10.1200/JCO.2018.36.15_suppl.e21013
Trial ID:
